Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lunai Bioworks Inc (LNAI)

Lunai Bioworks Inc (LNAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,103
  • Shares Outstanding, K 23,431
  • Annual Sales, $ 0 K
  • Annual Income, $ -178,010 K
  • EBIT $ -16 M
  • EBITDA $ 155 M
  • 60-Month Beta 0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings $0.13 on 11/14/25
  • Next Earnings Date 02/18/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Information Systems

Options Overview Details

View History
  • Implied Volatility 226.82% (+40.26%)
  • Historical Volatility 144.75%
  • IV Percentile 44%
  • IV Rank 16.66%
  • IV High 1,039.55% on 11/06/25
  • IV Low 64.32% on 11/17/25
  • Expected Move (DTE 22) 0.0425 (4.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,405
  • Open Int (30-Day) 3,542
  • Expected Range 0.9435 to 1.0285

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9601 +2.70%
on 11/26/25
1.5200 -35.13%
on 11/25/25
-0.2840 (-22.36%)
since 11/24/25
3-Month
0.8100 +21.73%
on 11/07/25
1.6600 -40.60%
on 11/20/25
-0.7400 (-42.87%)
since 09/24/25
52-Week
0.8100 +21.73%
on 11/07/25
14.0000 -92.96%
on 02/26/25
-9.3140 (-90.43%)
since 12/24/24

Most Recent Stories

More News
Medical Breakthroughs: 5 AI Innovators Redefining What's Possible

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61...

CBLL : 21.42 (+0.61%)
ONMD : 1.3300 (+3.10%)
VPT.VN : 0.120 (-4.00%)
LNAI : 0.9860 (-0.62%)
ABSI : 3.56 (+1.14%)
VPTDF : 0.0918 (+1.21%)
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity

LNAI : 0.9860 (-0.62%)
Financial Pressure Turns Healthcare AI From Pilots Into Profits

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...

VPT.VN : 0.120 (-4.00%)
CCLD : 3.09 (-1.28%)
ABSI : 3.56 (+1.14%)
LNAI : 0.9860 (-0.62%)
CAI : 28.24 (+0.86%)
VPTDF : 0.0918 (+1.21%)
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

SACRAMENTO, Calif. , Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three...

LNAI : 0.9860 (-0.62%)
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable therapies for aggressive cancers

LNAI : 0.9860 (-0.62%)
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines".

LNAI : 0.9860 (-0.62%)

Business Summary

Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company. Lunai Bioworks Inc., formerly known as RENOVARO INC, is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 1.1172
2nd Resistance Point 1.0845
1st Resistance Point 1.0353
Last Price 0.9860
1st Support Level 0.9534
2nd Support Level 0.9207
3rd Support Level 0.8715

See More

52-Week High 14.0000
Fibonacci 61.8% 8.9614
Fibonacci 50% 7.4050
Fibonacci 38.2% 5.8486
Last Price 0.9860
52-Week Low 0.8100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar